Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ Grass in seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
2019-001517-16Phase 3Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- May 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) comparing PQ Grass 27600 SU with Placebo (2 arms). Started May 2022; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2019-001517-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001517-16.